CD44: From adhesion molecules to signalling regulators

Nature Reviews Molecular Cell Biology

Volumn 4, Issue 1, 2003, Pages 33-45

  Ponta, Helmut ^a   Sherman, Larry ^b   Herrlich, Peter A ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CELL ADHESION MOLECULE; CYTOKINE; HERMES ANTIGEN; MEMBRANE PROTEIN;

ALTERNATIVE RNA SPLICING; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CYTOSKELETON; DELAYED HYPERSENSITIVITY; HUMAN; LIGAND BINDING; LYMPHOCYTE HOMING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD44; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS);

EID: 0037227965     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrm1004     Document Type: Review

References (145)

1. Juliano, R. L. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu. Rev. Pharmacol. Toxicol. 42, 283-323 (2002).
2. Naor, D., Slonov, R. V. & Ish-Shalom, D. in Advances in Cancer Research Vol. 70 (eds Vande Woude, G. F. & Klein, G.) 243-318 (Academic, San Diego, 1997).
3. Screaton, G. R. et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons Proc. Natl. Acad. Sci. USA 89, 12160-12164 (1992).
4. Stamenkovic, I., Aruffo, A., Arniot, M. & Seed, B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J. 10, 343-348 (1991).
5. Günthert, U. et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991). This paper shows a causal involvement of a CD44 variant in metastasis formation.
6. Borland, G., Ross, J. A. & Guy, K. Forms and functions of CD44. Immunology 93, 139-148 (1998).
7. Sherman, L., Sleeman, J., Herrlich, P. & Ponta, H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr. Opin. Cell Biol. 6, 726-733 (1994).
8. Sleeman, J., Kondo, K., Moll, J., Ponta, H. & Herrlich, P. Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44. J. Biol. Chem. 272, 31837-31844 (1997).
9. Skelton, T. P., Zeng, C., Nocks, A. & Stamenkovic, I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J. Cell Biol. 140, 431-446 (1998). This study provides a detailed analysis of the effect of glycosylation on CD44 binding to hyaluronan.
10. Lesley, J., Kincade, P. W. & Hyman, R. Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody. Eur. J. Immunol. 23, 1902-1909 (1993).
11. Lesley, J., English, N., Charles, C. & Hyman, R. The role of the CD44 cytoplasmic and transmembrane domains in constitutive and inducible hyaluronan binding. Eur. J. Immunol. 30, 245-253 (2000).
12. Okamoto, I. et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 18, 1435-1446 (1999).
13. König, H., Ponta, H. & Herrlich, P. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator EMBO J. 10, 2904-2913 (1998). This paper presents the first evidence for Ras-dependent splice regulation and the cis-elements responsible.
14. Weg-Remers, S., Ponta, H., Herrlich, P. & Konig, H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 20, 4194-4203 (2001).
15. Bennett, K. L. et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J. Cell Biol. 128, 687-698 (1995). Reference 15 shows that heparan-sulphate modification on the CD44 exon v3 allows binding of heparin-binding growth factors.
16. Sherman, L., Wainwright, D., Ponta, H. & Herrlich, P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev. 12, 1058-1071 (1998). This report shows that presentation of fibroblast growth factors by a heparan-sulphate-modified CD44 variant is required for limb development.
17. Yu, W. H., Woessner J. F. Jr, McNeish, J. D. & Stamenkovic, I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16, 307-323 (2002).
18. Liu, D. & Sy, M. S. Phorbol myristate acetate stimulates the dimenzation of CD44 involving a cysteine in the transmembrane domain. J. Immunol. 159, 2702-2711 (1997).
19. Neame, S. J., Uff, C. R., Sheikh, H., Wheatley, S. C. & Isacke, C. M. CD44 exhibits a cell type dependent interaction with triton X-100 insoluble, lipid rich, plasma membrane domains. J. Cell Sci. 108, 3127-3135 (1995).
20. Perschl, A., Lesley, J., English, N., Hyman, R. & Trowbridge, I. S. Transmembrane domain of CD44 is required for its detergent insolubility in fibroblasts. J. Cell Sci. 108, 1033-1041 (1995).
21. Tsukita, S., Oishi, K., Sato, N., Sagara, J. & Kawai, A. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol. 126, 391-401 (1994). This paper shows that ERM proteins link the cytoskeleton to the plasma membrane by binding to CD44.
22. Legg, J. W. & Isacke, C. M. Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44. Curr. Biol. 8, 705-708 (1998).
23. Yonemura, S. et al. Ezrin/redixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J. Cell. Biol. 140, 885-895 (1998).
24. 2- and calmodulin. Implications for modulation of CD44-ankyrin interaction. J. Biol. Chem. 272, 30322-30328 (1997).
25. Legg, J. W., Lewis, C. A., Parsons, M., Ng, T. & Isacke, C. M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nature Cell Biol. 4, 399-407 (2002). This study shows that site-specific serine phosphorylation of CD44 determines ezrin binding.
26. Neame, S. J. & Isacke, C. M. Phosphorylation of CD44 in vivo requires both Ser323 and Ser325, but does not regulate membrane localization or cytoskeletal interaction in epithelial cells. EMBO J. 11, 4733-4738 (1992).
27. Bourguignon, L. Y., Zhu, H., Shao, L., Zhu, D. & Chen, Y. W. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell. Motil. Cytoskeleton 43, 269-287 (1999).
28. Crepaldi, T., Gautreau, A., Comoglio, P. M., Louvard, D. & Arpin, M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithalial cells J. Cell Biol. 138, 423-434 (1997).
29. Ng, T. et al. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J. 20, 2723-2741 (2001).
30. Morrison, H. et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15, 968-980 (2001). This paper shows that CD44 mediates contact inhibition by binding to merlin.
31. Kissil, J. L., Johnson, K. C., Eckman, M. S. & Jacks, T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J. Biol. Chem. 277, 10394-10399 (2002).
32. Xiao, G. H., Beeser, A., Chernoff, J. & Testa, J. R. p21-activated kinase links Rac/Cdc42 signaling to merlin. J. Biol. Chem. 277, 883-886 (2002).
33. Shaw, R. J., McClatchey, A. I. & Jacks, T. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J. Biol. Chem. 273, 7757-7764 (1998). Reference 33 shows that the dephosphorylated form of merlin inhibits growth.
34. Sherman, L. et al. The CD44 proteins in embryonic development and in cancer. Curr. Top. Microbiol. Immunol. 213, 249-269 (1996).
35. Pure, E. & Cuff, C. A. A crucial role for CD44 in inflammation. Trends Mol. Med. 7, 213-221 (2001).
36. Schmits, R. et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 90, 2217-2233 (1997). This paper reports the disruption of the CD44 gene in the mouse.
37. Protin, U., Schweighoffer, T., Jochum, W. & Hilberg, F. CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J. Immunol. 163, 4917-4923 (1999).
38. Camenisch, T. D. et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 106, 349-360 (2000).
39. Wittig, B. M., Johansson, B., Zoller, M., Schwarzler, C. & Gunthert, U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 vanant exon 7 (CD44v7) J. Exp. Med. 191, 2053-2064 (2000).
40. Kaya, G., Rodriguez, I., Jorcano, J. L., Vassalli, P. & Stamenkovic, I. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation Genes Dev. 11, 996-1007 (1997). So far, this is the only work to show the 'conditional' inactivation of CD44 (by CD44 antisense sequence expression in skin).
41. Kaya, G., Rodriguez, I., Jorcano, J. L., Vassalli, P. & Stamenkovic, I. Cutaneous delayed-type hypersensitivity response is inhibited in transgenic mice with keratinocyte-specific CD44 expression defect. J. Invest. Dermatol. 113, 137-138 (1999).
42. Chen, D. et al. CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J. Immunol. 166, 5889-5897 (2001).
43. Fujii, K., Fujii, Y., Hubscher, S. & Tanaka, Y. CD44 is the physiological trigger of Fas up-regulation on rheumatoid synovial cells. J. Immunol. 167, 1198-1203 (2001).
44. Fuse, Y., Nishimura, H., Maeda, K. & Yoshikai, Y. CD95 (Fas) may control the expansion of activated T cells after elimination of bacteria in murine listeriosis. Infect. Immun. 65, 1883-1891 (1997).
45. Teder, P. et al. Resolution of lung inflammation by CD44. Science 296, 155-158 (2002).
46. Rafi-Janajreh, A. Q. et al. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J. Immunol. 163, 1619-1627 (1999).
47. Cuff, C. A. et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J. Clin. Invest. 108, 1031-1040 (2001).
48. Weber, G. F. et al. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Pes. 62, 2281-2286 (2002).
49. Wainwright, D. M. Growth factor presentation by CD44 variant proteins. Thesis, Imperial College of Science, Technology and Medicine, London (1998).
50. Zohar, R. et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell. Physiol. 184, 118-130 (2000).
51. Okamoto, I. et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am. J. Pathol. 160, 441-447 (2002)
52. Okamoto, I. et al. Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins. J. Biol. Chem. 274, 25525-25534 (1999).
53. Kawano, Y. et al. Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins. J. Biol. Chem. 275, 29628-29635 (2000).
54. Culty, M., Nguyen, H. A. & Underhill, C. B. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J. Cell Biol. 116, 1055-1062 (1992).
55. Yu, Q. & Starnenkovic, I. Localization of matrix metalloproteinese 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13, 35-48 (1999). This paper shows that MMP9 requires binding to CD44 at the membrane to promote cell invasion.
56. Yu, Q. & Starnenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163-176 (2000). Reference 56 shows that activation of MMP9 by binding to membrane-localized CD44 is required for proteolytic cleavage of the TGF-β precursor.
57. Yu, Q., Toole, B. P. & Starnenkovic, I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med. 186, 1985-1996 (1997).
58. Opanashuk, L. A. et al. Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action. J. Neurosci. 19, 133-146 (1999).
59. van der Voort, R. et al. Heparansulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J. Biol. Chem. 274, 6499-6506 (1999).
60. Katagiri, Y. U. et al. CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 59, 219-226 (1999).
61. Denhardt, D. T., Noda, M., O'Regan, A. W. Pavlin, D. & Berman, J. S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107, 1055-1061 (2001).
62. Lin, Y. H. et al. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol. Cell. Biol. 20, 2734-2742 (2000).
63. Pohl, M., Sakurai, H., Stuart, R. O. & Nigam, S. K. Role of hyaluronan and CD44 in in vitro branching morphogenesis of ureteric bud cells. Dev. Biol. 224, 312-325 (2000).
64. Schwarzler, C., Oliferenko, S. & Gunthert, U. Variant isoforms of CD44 are required in early thymocyte development. Eur. J. Immunol. 31, 2997-3005 (2001).
65. Cavallaro, U., Niedermeyer, J., Fuxa, M. & Christofori, G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nature Cell Biol. 3, 650-657 (2001).
66. Nestl, A. et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 61, 1569-1577 (2001).
67. Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074-3086 (2002). Reference 67 reports on a two-step mechanism for Met activation that involves v6 of CD44 and cytoplasmic-tail sequences.
68. Hartmann, G. et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo Curr. Biol. 8, 125-134 (1998); erratum in 8, R739 (1998).
69. Bourguignon, L. et al. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J. Biol. Chem. 272, 27913-27918 (1997).
70. Sherman, L. S., Rizvi, T.A., Karyala, S. & Ratner, N. CD44 enhances neuregulin signaling by Schwann cells. J. Cell Biol. 150, 1071-1084 (2000).
71. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386-390 (1995).
72. Riethmacher, D. et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389, 725-730 (1997).
73. Takahashi, K. et al. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/redixin/moesin initiates the activation of the Rho small G protein. J. Biol. Chem. 272, 23371-23375 (1997).
74. Takahashi, K. et al. Interaction of redixin with Rho small G protein GDP/GTP exchange protein Dbl. Oncogene 16, 3279-3284 (1998).
75. Bourguignon, L. Y., Zhu, H., Shao, L. & Chen, Y. W. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J. Biol. Chem. 275, 1829-1838 (2000).
76. Oliferenko, S., Kaverina, I., Small, J. V. & Huber, L. A. Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia. J. Cell Biol. 148, 1159-1164 (2000); erratum in 149, 241 (2000).
77. Bourguignon, L. Y., Zhu, H., Shao, L. & Chen, Y. W. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovanan tumor cell migration. J. Biol. Chem. 276, 7327-7336 (2001).
78. Bourguignon, L. Y. et al. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J. Biol. Chem. 276, 48679-48692 (2001).
79. Takahashi, K., Eto, H. & Tanabe, K. K. Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int. J. Cancer 80, 387-395 (1999).
80. Charrad, R. S. et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nature Med. 5, 669-676 (1999).
81. Yasuda, M., Tanaka, Y., Fujii, K. & Yasumoto, K. CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. Int Immunol. 13, 1309-1319 (2001).
82. Khaldoyanidi, S., Karakhanova, S., Sleeman, J., Herrlich, P. & Ponta, H. CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages. Blood 99, 3955-3961 (2002).
83. Taher, T. E. et al. Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. J. Biol. Chem. 271, 2863-2867 (1996). This article shows the association of the signalling component LCK with CD44 in activated T cells.
84. Ilangumaran, S., Briol, A. & Hoessli, D. C. CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes. Blood 91, 3901-3908 (1998).
85. Foger, N., Marhaba, R. & Zoller, M. Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J. Cell Sci. 114, 1169-1178 (2001).
86. Okamoto, I. et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J. Cell Biol. 155, 755-762 (2001).
87. Weiss, J. M. et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J. Cell Biol. 137, 1137-1147 (1997).
88. Kurz, S. M. et al. The impact of c-met/scatter factor receptor in dendritic cell migration. Eur. J. Immunol. 32, 1832-1838 (2002).
89. Sotiropoulos, A., Gineitis, D., Copeland, J. & Treisman, R. Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell 98, 159-169 (1999). This paper shows that there is a link between the actin cytoskeleton and signal transduction.
90. Lallemand, D. et al. Stress-activated protein kinases are negatively regulated by cell density. EMBO J. 17, 5615-5626 (1998).
91. Gineitis, D. & Treisman, R. Differential usage of signal transduction pathways defines two types of serum response factor target gene. J. Biol. Chem. 276, 24531-24539 (2001).
92. Bardwell, A. J., Flatauer, L. J., Matsukuma, K., Thorner, J. & Bardwell, L. A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission. J. Biol. Chem. 276, 10374-10386 (2001).
93. Trusolino, L., Bertotti, A. & Comoglio, P. M. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643-654 (2001).
94. Verfaillie, C. M., Benis, A., Iida, J., McGlave, P. B. & McCarthy, J. B. Adhesion of committed human hematopoietic progenitors to synthetic peptides from the C-terminal heparin-binding domain of fibronectin: cooperation between the integrin α4β1 and the CD44 adhesion receptor. Blood 84, 1802-1811 (1994).
95. Hofmann, M. et al. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 53, 1516-1521 (1993).
96. Hudson, D. L., Sleemen, J. & Watt, F. M. CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratincoytes and plays a role in intercellular adhesion. J. Cell Sci. 108, 1959-1970 (1995).
97. Arch, R. et al. Participation in normal immune responses of a splice variant of CD44 that encodes a metastasis-inducing domain. Science 257, 682-685 (1992). This paper shows that CD44 variants have decisive functions in eliciting an immune response.
98. Koopman, G. et al. Activated human lymphocytes and aggressive non-Hodgkin lymphomas express a homologue of the rat metastasis-associated variant of CD44. J. Exp. Med. 177, 897-904 (1993).
99. Matter, N. et al. Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. J. Biol. Chem. 275, 35353-35360 (2000).
100. Matter, N., Herrlich, P. & König, H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420, 691-695 (2002).
101. Bretscher, A., Edwards, K. & Fehon, R. G. ERM proteins and merlin: integrators at the cell cortex. Nature Rev. Mol. Cell Biol. 3, 586-599 (2002).
102. Gautreau, A., Louvard, D. & Arpin, M. ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr. Opin. Cell Biol. 14, 104-109 (2002).
103. Denker, S. P., Huang, D. C., Orlowski, J., Furthmayr, H. & Barber, D. L. Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H(+) translocation. Mol. Cell 6, 1425-1436 (2000).
104. Bono, P., Rubin, K., Higgins, J. M. & Hynes, R. O. Layilin, a novel integral membrane protein, is a hyaluronan receptor. Mol. Biol. Cell 12, 891-900 (2001).
105. Tsukita, S. & Yonemura, S. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J. Biol. Chem. 274, 34507-34510 (1999).
106. Trofatter, J. A. et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72, 791-800 (1993).
107. Rouleau, G. A. et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363, 515-521 (1993). References 106 and 107 report the cloning of merlin, the mutation of which - in one allele - is the cause of NF2.
108. Tran, Y. K. et al. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 59, 35-43 (1999).
109. Gusella, J. F., Ramesh, V., MacCollin, M. & Jacoby, L. B. Merlin: the neurofibromatosis 2 tumor suppressor. Biochim. Biophys. Acta 1423, M29-M36 (1999).
110. McClatchey, A. I. et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12, 1121-1133 (1998). The first indication of a role for merlin in the suppression of metastatic growth.
111. Giovannini, M. et al. Schwann cell hyperplasia and tumors in transganic mice expressing a naturally occurring mutant NF2 protein Genes Dev. 13, 978-986 (1999).
112. Cywes, C., Stamenkovic, I. & Wessels, M. R. CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J. Clin. Invest. 106, 995-1002 (2000).
113. Skoudy, A. et al. CD44 binds to the Shigella IpaB protein and participates in bacterial invasion of epithelial cells. Cell. Microbiol. 2, 19-33 (2000).
114. Shen, Y., Naujokas, M., Park, M. & Ireton, K. InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase. Cell 103, 501-510 (2000).
115. Dramsi, S. & Cossart, P. Intracellular pathogens and the actin cytoskeleton. Annu. Rev. Cell Dev. Biol. 14, 137-166 (1998).
116. Sechi, A. S., Wehland, J. & Small, J. V. The isolated comet tail pseudopodium of Listeria monocytogenes: a tail of two actin filament populations, long and axial and short and random. J. Cell Biol. 137, 155-167 (1997).
117. Wielenga, V. J. et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression Cancer Res. 53, 4754-4756 (1993).
118. Kim, H., Yang, X. L., Rosada, C., Hamilton, S. R. & August, J. T. CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation. Arch. Biochem. Biophys. 310, 504-507 (1994).
119. Wielenga, V. J. et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 154, 515-523 (1999).
120. Shtivelman, E. & Bishop, J. M. Expression of CD44 is repressed in neuroblastoma cells. Mol. Cell. Biol. 11, 5446-5453 (1991).
121. De Marzo, A. M., Bradshaw, C., Sauvageot, J., Epstein, J. I. & Miller, G. J. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 34, 162-168 (1998).
122. Gao, A. C., Lou, W., Dong, J. T. & Isaacs, J. T. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 57, 846-849 (1997).
123. Strobeck, M. W. et al. The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J. Biol. Chem. 276, 9273-9278 (2001).
124. Reisman, D. N. et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 21, 1196-1207 (2002).
125. Fraser, J. R., Laurent, T. C. & Laurent, U. B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242, 27-33 (1997).
126. Zhou, B., Weigel, J. A., Fauss, L. & Weigel, P. H. Identification of the hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 275, 37733-37741 (2000).
127. Banerji, S. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789-801 (1999).
128. Prevo, R., Banerji, S., Ferguson, D. J., Clasper, S. & Jackson, D. G. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J. Biol. Chem. 276, 19420-19430 (2001).
129. Termeer, C. et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 195, 99-111 (2002).
130. Hardwick, C. et al. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J. Cell Biol. 117, 1343-1350 (1992).
131. Hofmann, M. et al. Problems with RHAMM: a new link between surface adhesion and oncogenesis? Cell 95, 591-592 (1998); discussion in 95, 592-593 (1998).
132. Huang, L., Grammatikakis, N., Yoneda, M., Banerjee, S. D. & Toole, B. P. Molecular characterization of a novel intracellular hyaluronan-binding protein. J. Biol. Chem. 275, 29829-29839 (2000).
133. Peterson, R. M., Yu, Q., Stamenkovic, I. & Toole, B. P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol. 156, 2159-2167 (2000).
134. West, D. C., Hampson, I. N., Arnold, F. & Kumar, S. Angiogenesis induced by degradation products of hyaluronic acid. Science 228, 1324-1326 (1985). This report shows that low-molecular-weight hyaluronan fragments induce angiogenesis.
135. Lees, V. C., Fan, T. P. & West, D. C. Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan. Lab. Invest. 73, 259-266 (1995).
136. McKee, C. M. et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J. Clin. Invest. 98, 2403-2413 (1996).
137. Hodge-Dufour, J. et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J. Immunol. 159, 2492-2500 (1997).
138. Horton, M. R., Burdick, M. D., Strieter, R. M., Bao, C. & Noble, P. W. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN-γ in mouse macrophages. J. Immunol. 160, 3023-3030 (1998).
139. Rockey, D. C., Chung, J. J., McKee, C. M. & Noble, P. W. Stimulation of inducible nitric oxide synthase in rat liver by hyaluronan fragments Hepatology 27, 86-92 (1998).
140. Ohkawara, Y. et al. Activation and transforming growth factor-β production in eosinophils by hyaluronan. Am. J. Respir. Cell Mol. Biol. 23, 444-451 (2000).
141. Day, A. J. & Sheehan, J. K. Hyaluronan: polysaccharide chaos to protein organisation. Curr. Opin. Struct. Biol. 11, 617-622 (2001).
142. Banerji, S., Day, A. J., Kahmann, J. D. & Jackson, D. G. Characterization of a functional hyaluronan-binding domain from the human CD44 molecule expressed in Escherichia coli. Protein Expr. Purif. 14, 371-381 (1998).
143. Bajorath, J., Greenfield, B., Munro, S. B., Day, A. J. & Aruffo, A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J. Biol. Chem. 273, 338-343 (1998). The identification of the amino acids in CD44 that are responsible for hyaluronan binding.
144. Lokeshwar, V. B. & Bourguignon, L. Y. The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction. J. Biol. Chem. 267, 22073-22078 (1992).
145. Neame, S. J. & Isacke, C. M. The cytoplasmic tail of CD44 is required for basolateral localization in epithelial MDCK cells but does not mediate association with the detergent-insoluble cytoskeleton of fibroblasts. J. Cell Biol. 121, 1299-1310 (1993).